Scholar Rock Holding (SRRK) EBITDA (2017 - 2026)
Scholar Rock Holding (SRRK) recorded quarterly EBITDA of -$104.9 million in Q1 2026, down 15.31% quarter-over-quarter from -$91.0 million in Q4 2025, and down 40.35% on a YoY basis from -$175.9 million in Q1 2025.
Scholar Rock Holding (SRRK) EBITDA (2017 - 2026) Analysis & Trends
Scholar Rock Holding's EBITDA history runs 10 years deep, the most recent figure standing at -$104.9 million for Q1 2026.
- In Q1 2026, EBITDA fell 40.35% year-over-year to -$104.9 million; the TTM figure through Mar 2026 stood at -$408.2 million (down 54.62% YoY), while the FY2025 annual figure was -$378.0 million, down 53.52% from the prior year.
- EBITDA was -$104.9 million for Q1 2026 at Scholar Rock Holding, down from -$91.0 million in the prior quarter.
- In the past five years, EBITDA ranged from a high of -$8.1 million in Q1 2022 to a low of -$110.1 million in Q2 2025.
- Historically, EBITDA has averaged -$60.5 million across 5 years, with a median of -$57.0 million in 2024.
- The sharpest annual moves came in 2022 and 2023: EBITDA jumped 70.82% in 2022, then sank 381.27% in 2023.
- A 5-year view of EBITDA shows it stood at -$39.2 million in 2022, then retreated by 17.37% to -$46.0 million in 2023, then slumped by 44.36% to -$66.4 million in 2024, then tumbled by 36.98% to -$91.0 million in 2025, then retreated by 15.31% to -$104.9 million in 2026.
- The last three EBITDA figures came in at -$104.9 million (Q1 2026), -$91.0 million (Q4 2025), and -$102.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.92 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.63 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -752,618.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Scholar Rock Holding | 6.03 Bn | 5.55 Bn | - | -104.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -104.91 Mn |
| Dec 31, 2025 | -90.99 Mn |
| Sep 30, 2025 | -102.16 Mn |
| Jun 30, 2025 | -110.10 Mn |
| Mar 31, 2025 | -74.75 Mn |
| Dec 31, 2024 | -66.42 Mn |
| Sep 30, 2024 | -64.30 Mn |
| Jun 30, 2024 | -58.51 Mn |
| Mar 31, 2024 | -57.00 Mn |
| Dec 31, 2023 | -46.01 Mn |
| Sep 30, 2023 | -42.32 Mn |
| Jun 30, 2023 | -37.66 Mn |
| Mar 31, 2023 | -38.82 Mn |
| Dec 31, 2022 | -39.20 Mn |
| Sep 30, 2022 | -44.15 Mn |
| Jun 30, 2022 | -43.93 Mn |
| Mar 31, 2022 | -8.07 Mn |
| Dec 31, 2021 | -35.95 Mn |
| Sep 30, 2021 | -37.52 Mn |
| Jun 30, 2021 | -30.72 Mn |